Donald Trump Jr. is joining the board of prescription access platform BlinkRx, following 1789 Capital’s $140 million investment in the startup — making it the latest board the first son has joined since the election, NYNext has learned. Rather than take a job in his father’s administration, Trump Jr. has doubled down on his private sector presence. Since November, he has joined Omeed Malik’s 1789 Capital as well as the boards of e-commerce platform PublicSquare and firearms retailer Grab-a-Gun, The Post previously reported.
Trump Jr. and Malik told NYNext they are focused on solving many of the same problems government is working on, like making healthcare more affordable and encouraging technologic innovation, but doing so with private-sector solutions. “1789 invests in innovative technologies in areas of the economy, like education and healthcare, where excessive government involvement has actually led to poor outcomes and higher costs,” Malik said. “Our portfolio companies seek to rectify those problems using the free market.”
“It’s outrageous that hardworking Americans can’t get the medications they need,” Trump Jr. told NYNext. “BlinkRx has built the most advanced technology and business model to fix this broken system. I’m fully committed to doing everything in my power to ensure every single American has access to the medicine they deserve. This isn’t just a business — it’s a mission to solve one of healthcare’s biggest failures using entrepreneurship and innovation.” According to a BlinkRx spokesperson, its users save an average of $70 per prescription. The online pharmacy helps patients access medications at lower prices by working directly with pharmaceutical manufacturers and analyzing insurance costs to find the most affordable options. Sources told NYNext the company is expected to go public in the next two years.
